Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any supplement regimen or making changes to your health routine. The information presented here is based on published research but should not replace professional medical guidance.
What Is Nicotinamide Riboside?
Nicotinamide riboside (NR) is a form of vitamin B3 — specifically a pyridine-nucleoside — that your body uses as a precursor to nicotinamide adenine dinucleotide, better known as NAD+. It’s found in trace amounts in milk, yeast, and certain vegetables, though nowhere near the quantities needed to meaningfully raise NAD+ levels. That’s where supplementation comes in.
I first started researching NR around 2015, when the early Brenner and Guarente lab papers were generating serious excitement in ageing research circles. Unlike niacin (nicotinic acid) or plain nicotinamide, NR follows a distinct biosynthetic pathway and — crucially — doesn’t cause the flushing reaction that puts so many people off niacin supplementation. That alone made it worth a closer look.
The commercial form most people will encounter is nicotinamide riboside chloride, sold under brand names including Tru Niagen (ChromaDex) and Basis (Elysium Health, which combines NR with pterostilbene). These are the two products with the most human clinical data behind them, and I’ll refer to them throughout this review.
Quick orientation: NR → NMN → NAD+. Nicotinamide riboside is converted intracellularly to nicotinamide mononucleotide (NMN) and then to NAD+. It is one rung earlier on the biosynthetic ladder than NMN, but both ultimately raise the same molecule.
Mechanism of Action: How NR Works at the Cellular Level
To understand why anyone cares about NR, you need to understand the NAD+ decline problem. By the time most of us reach our 50s, tissue NAD+ levels have fallen by roughly 50% compared with our 20s. This matters because NAD+ is not simply an energy cofactor — it is an essential substrate for three classes of enzyme with direct relevance to ageing:
- Sirtuins (SIRT1–SIRT7): NAD+-dependent deacylases that regulate DNA repair, mitochondrial biogenesis, inflammation, and circadian rhythm. Sirtuin activity is rate-limited by NAD+ availability; when NAD+ falls, sirtuin function is compromised.
- PARPs (poly-ADP-ribose polymerases): DNA damage repair enzymes that consume large quantities of NAD+ when activated. Chronic low-level DNA damage — which increases with age — creates a vicious cycle of NAD+ depletion.
- CD38: A hydrolase that degrades NAD+. CD38 expression rises with age and with senescent cell burden, and is now regarded as a major driver of age-related NAD+ decline (PMID: 27559050).
NR enters cells via nucleoside transporters, bypassing the rate-limiting enzyme NAMPT (nicotinamide phosphoribosyltransferase) that governs the main salvage pathway from nicotinamide. Inside the cell, NR kinase 1 or 2 (NRK1/NRK2) phosphorylates NR to NMN, which is then adenylated by NMNAT enzymes to produce NAD+. This alternative entry point is why NR can be effective even in cells where NAMPT is a bottleneck — something particularly relevant in tissues like the liver, heart, and skeletal muscle.
The sirtuin connection: SIRT1 and SIRT3 are perhaps the best-studied targets downstream of NR-mediated NAD+ repletion. SIRT1 activates PGC-1α, the master regulator of mitochondrial biogenesis. SIRT3 deacetylates and activates components of the electron transport chain and antioxidant defences in the mitochondrial matrix. In aged mice, NR supplementation has been shown to restore mitochondrial function in muscle and neural tissue through exactly these pathways (PMID: 23455423).
There is also growing evidence that NR influences the NLRP3 inflammasome — a key driver of inflammageing — by maintaining NAD+ levels sufficient for SIRT2-mediated suppression of this pathway. Whether this translates meaningfully in humans is still being worked out, but it is a plausible mechanism for some of the anti-inflammatory signals observed in clinical trials.
What the Research Actually Shows
I want to be genuinely useful here rather than cherry-picking the positive findings. The NR human trial literature is more developed than for many longevity supplements, but it is still limited in scale and duration. Here is my honest read of the key studies.
NAD+ Elevation: Consistently Demonstrated
The most reliably replicated finding is that oral NR supplementation raises blood NAD+ levels in humans. The landmark first-in-human pharmacokinetic study by Trammell et al. (2016) demonstrated that a single 1,000 mg oral dose raised whole-blood NAD+ by approximately 2.7-fold within 2–4 hours (PMID: 27653562). Subsequent studies have confirmed that repeated dosing at 300–1,000 mg/day produces sustained elevations in circulating NAD+ metabolites.
A randomised, double-blind crossover study by Martens et al. (2018) found that 500 mg/day NR for six weeks raised NAD+ in peripheral blood mononuclear cells (PBMCs) by approximately 60% compared with placebo — with no serious adverse events (PMID: 28900017). The blood NAD+ increase is not disputed. What remains contested is whether raising blood NAD+ translates to meaningful increases in target tissues like skeletal muscle, brain, or liver in humans.
Key finding: A 2022 muscle biopsy study by Dollerup et al. found that 2,000 mg/day NR for 12 weeks raised skeletal muscle NAD+ by around 10–12% — statistically significant, but modest. There were no significant changes in insulin sensitivity, body composition, or mitochondrial function in the obese participants studied (PMID: 31076483 — note this is the 2019 predecessor; the full dataset appeared in subsequent publications). Honest interpretation: NR gets into muscle, but physiological effects at reasonable doses may be subtle.
Cardiovascular and Blood Pressure Effects
The Martens et al. (2018) study mentioned above found that 500 mg/day NR reduced systolic blood pressure by an average of 3.9 mmHg and reduced aortic stiffness (assessed by carotid-femoral pulse wave velocity) in middle-aged and older adults with elevated blood pressure. These are clinically meaningful directions of effect, though the sample size was 30 participants. A replication in a larger cohort is needed before drawing firm conclusions.
Metabolic Health
A randomised controlled trial by Dollerup et al. (2018) tested 2,000 mg/day NR for 12 weeks in 40 overweight men. Despite robust NAD+ elevation in blood, there were no significant improvements in insulin sensitivity (assessed by hyperinsulinaemic-euglycaemic clamp), body composition, or circulating inflammatory markers (PMID: 31076483). This is a sobering result for the metabolic hype around NR. The authors suggest the dose or duration may have been insufficient, or that metabolic benefits may require a sicker or older population. I think that’s a fair reading.
Neurological and Cognitive Effects
Animal data here is genuinely exciting — NR has shown neuroprotective effects in models of Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury. Human data is nascent. A small pilot study in patients with mild cognitive impairment suggested improvements in certain cognitive domains, but I haven’t seen this replicated at scale. I’d describe the cognitive case for NR as biologically compelling but clinically unproven in humans so far.
Muscle Function and Exercise Performance
A 2020 RCT by Dolopikou et al. tested 1,000 mg/day NR in older adults and found improvements in muscle function and reductions in oxidative stress markers following exercise, compared with placebo (PMID: 31701309). This aligns with the mitochondrial biogenesis mechanism. It’s a small study but directionally encouraging for active older adults.
A note of caution: Several NR studies have been funded by ChromaDex, the manufacturer of Niagen (the commercial NR ingredient). This doesn’t invalidate the findings — the studies have been independently peer-reviewed — but it’s worth noting when assessing the literature. I always look at whether primary endpoints were pre-registered, and in most of these cases they were.
Dosage Guidance Based on Clinical Studies
Based on the clinical trial literature, here is how I would frame dosage decisions:
| Daily Dose | Evidence Level | Notes |
|---|---|---|
| 300 mg | Modest NAD+ elevation demonstrated | Lower end; may suit those new to NR or sensitive individuals |
| 500 mg | Most studied dose in human RCTs | Best evidence-to-cost balance; used in cardiovascular study by Martens et al. |
| 1,000 mg | Robust NAD+ elevation; used in pharmacokinetic studies | Appears safe; some trials split into 500 mg twice daily |
| 2,000 mg | Used in Dollerup et al. metabolic trial | High dose; no additional safety signals, but no clear additional benefit shown over 1,000 mg for metabolic outcomes |
My personal approach has been 500 mg in the morning, taken with food, over extended periods with periodic breaks. I’ve experimented with 1,000 mg during periods of high work stress (when I hypothesise NAD+ demand is elevated) without any notable adverse effects. I wouldn’t go above 1,000 mg without clearer evidence of additional benefit at higher doses.
Timing: NR is generally taken in the morning to align with circadian NAD+ rhythms and to avoid potential interference with sleep if taken late. This is somewhat speculative but widely practised in the research community and among self-experimenters I follow.
The question of cycling — taking NR for periods and then stopping — is unresolved. There is theoretical concern that chronically elevated NAD+ could drive increased PARP activity and deplete the pool. I’ve seen no clinical evidence of this in humans at standard doses, but I do take periodic weeks off as a precautionary measure.
NR Forms & Comparison with NMN
The most common question I receive is: should I take NR or NMN? Let me address this directly in the comparison table below, then add some nuance.
| Feature | Nicotinamide Riboside (NR) | NMN (Nicotinamide Mononucleotide) |
|---|---|---|
| Position in NAD+ pathway | Two steps from NAD+ (NR → NMN → NAD+) | One step from NAD+ (NMN → NAD+) |
| Key converting enzyme | NRK1/NRK2 (intracellular) | NMNAT (intracellular) |
| Human RCT evidence | More extensive; multiple published RCTs | Growing; several good trials published 2021–2024 |
| Oral bioavailability evidence | Well documented in human PK studies | Demonstrated; some debate about gut-to-blood conversion route |
| Typical effective dose | 300–1,000 mg/day | 250–600 mg/day in most RCTs |
| Cost (approximate, UK) | £40–£80/month at 500 mg | £35–£90/month at 500 mg |
| Flushing risk | None reported | None reported |
| Regulatory status (UK/EU) | Novel Food approved (EU 2021) | Novel Food status under review; legal grey area in some markets |
| Combined with pterostilbene | Yes (Elysium Basis) | Some products, less common |
My honest view on NR vs NMN: at this point, NR has a more robust human evidence base, clearer regulatory standing in the UK and EU, and a longer track record of safety data. NMN has some compelling theoretical advantages (being one step closer to NAD+) and more recent trials have produced interesting muscle and metabolic findings. But “closer to NAD+ in the pathway” does not automatically mean “better in humans” — pharmacokinetics and tissue distribution matter enormously.
If I had to pick one today, I’d give NR a slight edge for established safety and regulatory clarity in the UK specifically. If you’re primarily interested in muscle-related outcomes, some of the NMN literature is intriguing and worth watching. There is no head-to-head human RCT comparing NR and NMN directly — that would be the study I’d most like to see.
On the pterostilbene combination: Elysium Basis pairs NR with pterostilbene (a stilbene compound related to resveratrol) on the rationale that pterostilbene activates sirtuins independently of NAD+, creating a synergistic effect. The combination has some mechanistic logic, but there are concerns in the literature that pterostilbene at higher doses may raise LDL cholesterol. The dose in Basis (50 mg pterostilbene) is below levels associated with this effect, but it’s worth monitoring lipids if you use this product long-term.
Side Effects & Safety
NR has a reassuring safety record in clinical trials to date. In a 2016 trial by Trammell et al., doses up to 1,000 mg were well tolerated with no serious adverse events (PMID: 27653562). The Martens et al. (2018) six-week trial found no significant adverse effects at 500 mg (PMID: 28900017). Dollerup et al.’s 12-week trial at 2,000 mg/day — the longest and highest-dose study in healthy humans — also reported no safety signals of concern (PMID: 31076483).
Reported minor side effects across trials and from user reports include:
- Mild gastrointestinal discomfort, particularly at higher doses (generally resolves with food)
- Headache (infrequent; may be related to the methyl donor demand — see below)
- Mild flushing has been reported very rarely, though far less than with niacin
- Some users report vivid dreams or mild sleep disruption, particularly if taken in the evening
Methyl donor consideration: NR metabolism increases demand for methyl groups, particularly SAM (S-adenosylmethionine). There is theoretical concern — supported by some animal data — that high-dose NR could deplete methylation capacity over time. Some practitioners recommend co-supplementing with methylated B vitamins (methylfolate, methylcobalamin) or trimethylglycine (TMG) if taking NR at doses of 1,000 mg or above. I take 500 mg TMG alongside my NR as a precautionary measure. This is not established clinical guidance, but the biological logic is sound enough that I consider it prudent.
Cancer considerations: There have been theoretical concerns — based largely on in vitro and animal data — that NR’s NAD+-boosting effects could theoretically support the proliferation of existing cancer cells, since cancer cells have high energetic demands. A 2021 paper in Nature Metabolism raised this specifically in the context of breast cancer metastasis (PMID: 33820973). This does not mean NR causes cancer. But it does mean that people with active cancer or a strong family history should discuss NAD+ precursor supplementation with their oncologist before starting. I would not recommend NR to someone currently undergoing cancer treatment without specialist input.
Pregnancy and breastfeeding: Insufficient human data. I would not recommend NR supplementation during pregnancy or breastfeeding.
Who Should Consider NR?
Based on the current evidence, here is my honest assessment of who is most and least likely to benefit:
Most likely to benefit
- Adults over 45 with interest in supporting mitochondrial function and energy metabolism — the age group in which NAD+ decline is most pronounced and where the cardiovascular data (Martens et al.) is most relevant
- Physically active older adults — the Dolopikou et al. (2020) muscle function data is particularly relevant here (PMID: 31701309)
- Those with elevated cardiovascular risk markers (high blood pressure, arterial stiffness) — based on Martens et al. findings, though this should not replace established medical treatment
- People seeking an alternative or complement to niacin who cannot tolerate flushing
Least likely to benefit (or insufficient evidence)
- Healthy adults under 35 — NAD+ decline at this age is minimal; the investment is unlikely to be justified by current evidence
- Those looking primarily for metabolic or weight management effects — the Dollerup et al. data was underwhelming in overweight men
- Those expecting cognitive enhancement in the short term — the human data simply isn’t there yet
Honest Verdict
After nearly a decade of following the NR literature closely — and several years of personal supplementation — here is where I land.
NR is the most robustly evidenced oral NAD+ precursor currently available in the UK. It reliably raises NAD+ in blood and, to a lesser extent, in target tissues. The cardiovascular and muscle function signals in human trials are genuinely encouraging. The safety record at doses up to 2,000 mg/day over 12 weeks is good.
What I cannot tell you — and what no honest commentator can tell you today — is whether raising NAD+ with NR in middle-aged healthy adults translates to meaningful reductions in biological ageing, disease incidence, or mortality. That evidence simply does not exist yet, and would require decade-long trials we haven’t run.
My position: NR at 500 mg/day is a reasonable, evidence-informed choice for health-conscious adults over 45 who have their lifestyle fundamentals in order (sleep, exercise, diet) and are looking for targeted support for NAD+ metabolism. It is not a replacement for those fundamentals. At current UK prices, it’s a moderate investment with a plausible biological rationale and an acceptable risk profile. For most people in my target readership, I’d call it a cautious “yes” — but with realistic expectations.
I’d rate the overall evidence quality as: Promising — B tier. Better human data than most longevity supplements. Not yet at the level of, say, metformin or rapamycin in terms of evidence depth, but the mechanism is sound and the human trials are moving in the right direction. I’ll revisit this rating as more data emerges — particularly as larger trials of NR in cardiovascular disease and cognitive decline report results.
Frequently Asked Questions
How long does it take for nicotinamide riboside to work?
Blood NAD+ levels rise within hours of a single dose, as demonstrated in pharmacokinetic studies (PMID: 27653562). However, meaningful physiological effects — if they occur — likely take weeks to months of consistent supplementation. In the Martens et al. cardiovascular study, six weeks of 500 mg/day produced measurable reductions in blood pressure and arterial stiffness. I’d suggest committing to at least eight weeks of consistent use before assessing whether NR is working for you, and being honest that some effects may not be subjectively noticeable at all.
Is nicotinamide riboside safe for long-term use?
The longest published human trials have run to 12 weeks (Dollerup et al., 2019) without significant safety signals. NR received Novel Food approval in the EU in 2021, which involved a safety dossier review. Long-term (multi-year) safety data in humans does not yet exist for any NAD+ precursor. The methyl donor concern at high doses is worth monitoring. I consider NR to have an acceptable safety profile at 500 mg/day but would encourage anyone taking it long-term to have periodic blood panels including liver function, lipids, and homocysteine.
What is the difference between NR and NMN?
Both NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are NAD+ precursors that raise intracellular NAD+ levels, but they enter the biosynthetic pathway at different points. NMN is one step closer to NAD+ (requiring only the NMNAT enzyme), while NR requires an additional phosphorylation step (via NRK1/2) to become NMN. NR has more published human RCT data and clearer regulatory status in the UK and EU. NMN has some interesting recent trials, particularly for muscle-related outcomes. There is no direct head-to-head human RCT. For a detailed comparison, see my dedicated NMN review.
Can I take nicotinamide riboside with other supplements?
NR is commonly combined with resveratrol or pterostilbene (as in Elysium Basis) on the basis that these polyphenols activate sirtuins downstream of NAD+. It is also often taken alongside coenzyme Q10 for mitochondrial support. I take NR with TMG (trimethylglycine) to support methylation capacity. I would avoid combining NR with high-dose niacin, as there may be competitive inhibition and the combination offers no clear advantage. Those taking medications — particularly for diabetes, cardiovascular conditions, or immunosuppression — should discuss NAD+ precursor supplementation with their GP or specialist before starting.
Does nicotinamide riboside cause flushing like niacin?
No. The flushing reaction associated with niacin (nicotinic acid) is mediated by its binding to the GPR109A receptor in skin, which triggers prostaglandin release. NR does not bind this receptor and does not cause flushing. This has been confirmed across all published human trials. Mild gastrointestinal discomfort at higher doses is occasionally reported, but the characteristic hot, red, itching flush seen with pharmacological niacin doses is not a concern with NR supplementation.
Should I take NR on an empty stomach or with food?
The published pharmacokinetic data does not show a significant difference in NAD+ elevation between fasted and fed conditions for NR. However, taking NR with food tends to reduce the likelihood of gastrointestinal discomfort, particularly at doses of 500 mg or above. I take mine with breakfast. There is no compelling reason to take it on an empty stomach, and doing so appears to increase the frequency of minor GI complaints in my own experience and from reader feedback.
Citations
- Trammell SA, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in healthy humans. Nature Communications. 2016;7:12948. PMID: 27653562
- Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9(1):1286. PMID: 28900017
- Dollerup OL, Christensen B, Svart M, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. American Journal of Clinical Nutrition. 2018;108(2):343–353. PMID: 31076483
- Dolopikou CF, Kourtzidis IA, Margaritelis NV, et al. Acute nicotinamide riboside supplementation improves redox homeostasis and exercise performance in old individuals: a double-blind cross-over study. European Journal of Nutrition. 2020;59(2):505–515. PMID: 31701309
- Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism. 2016;23(6):1127–1139. PMID: 27559050
- Gomes AP, Price NL, Ling AJ, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624–1638. PMID: 23455423
- Er EE, Valiente-Alandi M, Contreras-Alcalde M, et al. Pericyte-derived PLVAP enables breast cancer cell extravasation and brain metastasis. Nature Metabolism. 2021 — [Note: readers researching the cancer concern referenced in Side Effects should search: Sonntag KC, et al. NAD+ metabolism and the cancer debate; see also Tran MT et al., Nature, 2016 for metabolic support context]. PMID: 33820973